Insiders who reported open-market trades in the last 12 months at the companies Joseph E. Gilliam files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Thomas William Burns - $31.63M in GKOS purchases and sales in the last 12 months
Joseph E. Gilliam is a corporate insider, tracked as Director of Caris Life Sciences, Inc. (CAI). InsiderAlpha holds 19 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Joseph E. Gilliam submitted recently?
2 primary Form 4 filings in the last 90 days, covering 2 companies.
Has Joseph E. Gilliam been buying or selling stock?
Recorded transactions: 0 open-market purchases and 12 open-market sales ($18.05M) across all tracked filings.
Joseph E. Gilliam is Director of Caris Life Sciences, Inc. (CAI). 19 SEC Form 4 filings on record going back to 2024, most recently on 14 August 2026. Most recent open-market trade: sold $5.78M of GKOS on 13 August 2026. Lifetime open-market sales: $18.05M.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by Joseph E. Gilliam.
InsiderAlpha's records for Joseph E. Gilliam go back to 2024: 19 primary Form 4 filings, an average of 6.3 per year. 20 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
